Press Releases

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Presentation to focus on mechanism of action of anti-tumor activity for lead asset YB-200 RIEHEN, SWITZERLAND, April 26, 2023 ─...

Apr 26, 2023

Martin E. Zuzulo to guide drug development operations for preclinical-stage biotech company RIEHEN, SWITZERLAND, April 11, 2023 –...

Apr 11, 2023

Participation in the international program guides startups in creating and developing business traction RIEHEN, SWITZERLAND, March 8,...

Mar 8, 2023

Mitsuro Kanda, MD, PhD, and Vishal Khairnar, PhD, join growing biotech company developing antibodies as therapies against various cancers...

Mar 2, 2023

Ymmunobio developed CEACAM antibody YB-200 for the treatment of hepatocellular carcinoma (HCC) RIEHEN, SWITZERLAND, February 28, 2023 ─...

Feb 28, 2023

Medical oncologist & CMO at Transcenta joins the board of growing biotech company February 16, 2023 ─ Ymmunobio, a preclinical stage...

Feb 16, 2023